Company Filing History:

7 out of 377

Aventis Pharma S.a.

patents

2 out of 207

Aventis Pharmaceuticals Inc.

Years Active: 2005-2015

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9221817 - Anti-cancer compound and pharmaceutical composition containing the same (2015-12-29),

2. 9073917 - Anti-cancer compound and pharmaceutical composition containing the same (2015-07-07),

3. 8163768 - 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them (2012-04-24),

4. 8110571 - Benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as c-MET inhibitors (2012-02-07),

5. 7943616 - Azaindoles for inhibiting aurora2 and other kinases (2011-05-17),

6. 7595320 - Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof (2009-09-29),

7. 7491710 - Organophosphorus derivatives of indazoles and use thereof as medicinal products (2009-02-17),

8. 7435820 - [object Object] (2008-10-14),

9. 7109340 - Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use (2006-09-19),

10. 7041668 - Substituted benzimidazole compounds and their use for the treatment of cancer (2006-05-09),

11. 6897207 - Azaindoles (2005-05-24),

Title: The Innovative Contributions of Francois Clerc

Introduction

Francois Clerc is a notable inventor based in Antony, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-cancer compounds. With a total of 11 patents to his name, Clerc's work has the potential to impact cancer treatment significantly.

Latest Patents

One of Clerc's latest patents is focused on an anti-cancer compound and pharmaceutical composition. This invention relates to a compound of formula (I), specifically in its levorotatory form (1a). The compound exhibits a rotatory power of [α]D=−38.6+0.7 at a concentration of 0.698 mg/ml in methanol. It can exist as a base or an acid addition salt, particularly a pharmaceutically acceptable acid. This compound serves as a selective Aurora A and B kinase inhibitor, making it a promising candidate for use as an anticancer drug.

Career Highlights

Francois Clerc has worked with prominent companies in the pharmaceutical industry, including Aventis Pharma S.A. and Aventis Pharmaceuticals Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Clerc has collaborated with notable colleagues such as Frank Halley and Jean-Christophe Carry. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Francois Clerc's innovative work in developing anti-cancer compounds showcases his dedication to advancing medical science. His contributions have the potential to lead to significant improvements in cancer treatment options.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.